Even if you’ve considered route of delivery, frequency and duration of treatment, and the nature of your API, a thorough preclinical safety assessment of innovative ocular therapies can be challenging. Few organizations have the internal resources or knowledge to obtain the data required for approval, much less perform these evaluations with any efficiency.
Learn how to minimize risk to patients and your program during our special 1-hour presentation. You’ll discover the data, study designs, and technologies that will help you satisfy rigorous regulatory requirements and meet the ocular toxicologists with the knowledge and experience to support your program. We hope you will join us.
Mark Vézina, BSc
Director, Ocular and Neuroscience
Philippe Ancian, PhD
Senior Director, Biomarkers